Literature DB >> 16373659

Impact of vaccine-induced mucosal high-avidity CD8+ CTLs in delay of AIDS viral dissemination from mucosa.

Igor M Belyakov1, Vladimir A Kuznetsov, Brian Kelsall, Dennis Klinman, Marcin Moniuszko, Michael Lemon, Phillip D Markham, Ranajit Pal, John D Clements, Mark G Lewis, Warren Strober, Genoveffa Franchini, Jay A Berzofsky.   

Abstract

Natural HIV transmission occurs through mucosa, but it is debated whether mucosal cytotoxic T lymphocytes (CTLs) can prevent or reduce dissemination from the initial mucosal site to the systemic circulation. Also, the role of CTL avidity in mucosal AIDS viral transmission is unknown. To address these questions, we used delay in acute-phase peak viremia after intrarectal challenge as an indicator of systemic dissemination. We found that a peptide-prime/poxviral boost vaccine inducing high levels of high-avidity mucosal CTLs can have an impact on dissemination of intrarectally administered pathogenic SHIV-ku2 in macaques and that such protection correlates better with mucosal than with systemic CTLs and particularly with levels of high-avidity mucosal CTLs.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16373659      PMCID: PMC1895757          DOI: 10.1182/blood-2005-11-4374

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  56 in total

1.  Interplay of cytokines and adjuvants in the regulation of mucosal and systemic HIV-specific CTL.

Authors:  I M Belyakov; J D Ahlers; J D Clements; W Strober; J A Berzofsky
Journal:  J Immunol       Date:  2000-12-01       Impact factor: 5.422

2.  Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine.

Authors:  R R Amara; F Villinger; J D Altman; S L Lydy; S P O'Neil; S I Staprans; D C Montefiori; Y Xu; J G Herndon; L S Wyatt; M A Candido; N L Kozyr; P L Earl; J M Smith; H L Ma; B D Grimm; M L Hulsey; J Miller; H M McClure; J M McNicholl; B Moss; H L Robinson
Journal:  Science       Date:  2001-04-06       Impact factor: 47.728

3.  High-avidity CTL exploit two complementary mechanisms to provide better protection against viral infection than low-avidity CTL.

Authors:  M Derby; M Alexander-Miller; R Tse; J Berzofsky
Journal:  J Immunol       Date:  2001-02-01       Impact factor: 5.422

4.  Mucosal AIDS vaccine reduces disease and viral load in gut reservoir and blood after mucosal infection of macaques.

Authors:  I M Belyakov; Z Hel; B Kelsall; V A Kuznetsov; J D Ahlers; J Nacsa; D I Watkins; T M Allen; A Sette; J Altman; R Woodward; P D Markham; J D Clements; G Franchini; W Strober; J A Berzofsky
Journal:  Nat Med       Date:  2001-12       Impact factor: 53.440

5.  ALVAC-SIV-gag-pol-env-based vaccination and macaque major histocompatibility complex class I (A*01) delay simian immunodeficiency virus SIVmac-induced immunodeficiency.

Authors:  R Pal; D Venzon; N L Letvin; S Santra; D C Montefiori; N R Miller; E Tryniszewska; M G Lewis; T C VanCott; V Hirsch; R Woodward; A Gibson; M Grace; E Dobratz; P D Markham; Z Hel; J Nacsa; M Klein; J Tartaglia; G Franchini
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

6.  CD8(+) lymphocytes from simian immunodeficiency virus-infected rhesus macaques recognize 14 different epitopes bound by the major histocompatibility complex class I molecule mamu-A*01: implications for vaccine design and testing.

Authors:  T M Allen; B R Mothé; J Sidney; P Jing; J L Dzuris; M E Liebl; T U Vogel; D H O'Connor; X Wang; M C Wussow; J A Thomson; J D Altman; D I Watkins; A Sette
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

7.  Sexual transmission and propagation of SIV and HIV in resting and activated CD4+ T cells.

Authors:  Z Zhang; T Schuler; M Zupancic; S Wietgrefe; K A Staskus; K A Reimann; T A Reinhart; M Rogan; W Cavert; C J Miller; R S Veazey; D Notermans; S Little; S A Danner; D D Richman; D Havlir; J Wong; H L Jordan; T W Schacker; P Racz; K Tenner-Racz; N L Letvin; S Wolinsky; A T Haase
Journal:  Science       Date:  1999-11-12       Impact factor: 47.728

8.  Quantitative evaluation of simian immunodeficiency virus infection using NASBA technology.

Authors:  J W Romano; R N Shurtliff; E Dobratz; A Gibson; K Hickman; P D Markham; R Pal
Journal:  J Virol Methods       Date:  2000-04       Impact factor: 2.014

Review 9.  A rational basis for mucosal vaccination against HIV infection.

Authors:  T Lehner; L Bergmeier; Y Wang; L Tao; E Mitchell
Journal:  Immunol Rev       Date:  1999-08       Impact factor: 12.988

Review 10.  Immunobiology of mucosal HIV infection and the basis for development of a new generation of mucosal AIDS vaccines.

Authors:  Igor M Belyakov; Jay A Berzofsky
Journal:  Immunity       Date:  2004-03       Impact factor: 31.745

View more
  53 in total

1.  Long-lasting humoral and cellular immune responses and mucosal dissemination after intramuscular DNA immunization.

Authors:  Vainav Patel; Antonio Valentin; Viraj Kulkarni; Margherita Rosati; Cristina Bergamaschi; Rashmi Jalah; Candido Alicea; Jacob T Minang; Matthew T Trivett; Claes Ohlen; Jun Zhao; Marjorie Robert-Guroff; Amir S Khan; Ruxandra Draghia-Akli; Barbara K Felber; George N Pavlakis
Journal:  Vaccine       Date:  2010-05-06       Impact factor: 3.641

2.  Innate and adaptive immune correlates of vaccine and adjuvant-induced control of mucosal transmission of SIV in macaques.

Authors:  Yongjun Sui; Qing Zhu; Susan Gagnon; Amiran Dzutsev; Masaki Terabe; Monica Vaccari; David Venzon; Dennis Klinman; Warren Strober; Brian Kelsall; Genoveffa Franchini; Igor M Belyakov; Jay A Berzofsky
Journal:  Proc Natl Acad Sci U S A       Date:  2010-05-10       Impact factor: 11.205

3.  Virus-specific T cell responses in macaques acutely infected with SHIV(sf162p3).

Authors:  Bapi Pahar; Xiaolei Wang; Jason Dufour; Andrew A Lackner; Ronald S Veazey
Journal:  Virology       Date:  2007-02-16       Impact factor: 3.616

4.  High-functional-avidity cytotoxic T lymphocyte responses to HLA-B-restricted Gag-derived epitopes associated with relative HIV control.

Authors:  Christoph T Berger; Nicole Frahm; David A Price; Beatriz Mothe; Musie Ghebremichael; Kari L Hartman; Leah M Henry; Jason M Brenchley; Laura E Ruff; Vanessa Venturi; Florencia Pereyra; John Sidney; Alessandro Sette; Daniel C Douek; Bruce D Walker; Daniel E Kaufmann; Christian Brander
Journal:  J Virol       Date:  2011-07-13       Impact factor: 5.103

Review 5.  New approaches to design HIV-1 T-cell vaccines.

Authors:  Hélène Perrin; Glenda Canderan; Rafick-Pierre Sékaly; Lydie Trautmann
Journal:  Curr Opin HIV AIDS       Date:  2010-09       Impact factor: 4.283

6.  Using 3 TLR ligands as a combination adjuvant induces qualitative changes in T cell responses needed for antiviral protection in mice.

Authors:  Qing Zhu; Colt Egelston; Susan Gagnon; Yongjun Sui; Igor M Belyakov; Dennis M Klinman; Jay A Berzofsky
Journal:  J Clin Invest       Date:  2010-01-25       Impact factor: 14.808

Review 7.  HIV infection and the gastrointestinal immune system.

Authors:  J M Brenchley; D C Douek
Journal:  Mucosal Immunol       Date:  2008-01       Impact factor: 7.313

8.  AIDSVAX immunization induces HIV-specific CD8+ T-cell responses in high-risk, HIV-negative volunteers who subsequently acquire HIV infection.

Authors:  Norman G Jones; Allan DeCamp; Peter Gilbert; Michael L Peterson; Marc Gurwith; Huyen Cao
Journal:  Vaccine       Date:  2008-12-09       Impact factor: 3.641

Review 9.  Crosstalk between adaptive and innate immune cells leads to high quality immune protection at the mucosal borders.

Authors:  Hilde Cheroutre; Yujun Huang
Journal:  Adv Exp Med Biol       Date:  2013       Impact factor: 2.622

Review 10.  Memories that last forever: strategies for optimizing vaccine T-cell memory.

Authors:  Jeffrey D Ahlers; Igor M Belyakov
Journal:  Blood       Date:  2009-11-10       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.